Survivin and HLA-I expression predicts survival of patients with clear cell renal cell carcinoma

Sulai Liu,Lin Qi,Qiuxia Yu,Yinghui Song,Weiqing Han,Xiongbing Zu,Shusuan Jiang,Jinyang Yuan,Fuhua Zeng,Yu Xie

DOI: https://doi.org/10.1007/s13277-014-2058-y

2014-01-01

Tumor Biology

Abstract:Altered expression of survivin and leukocyte antigen class I (HLA-I) proteins is associated with tumor progression. This study investigated their expressions in clear cell renal cell carcinoma (ccRCC) tissues for association with a clinical significance of ccRCC patients. Ninety ccRCC and 20 normal tissue samples (i.e., control) were immunohistochemically stained for survivin and HLA-I expression for an association with clinicopathological data and survival of ccRCC patients. Survivin protein was expressed in 82.2 % (74/90) of ccRCC tissue samples compared to 0 % in the normal tissues, and HLA-I protein was expressed in 90 % (18/20) of the normal tissues vs. 67.8 % (61/90) in ccRCC samples. Survivin expression was associated with tumor grade, stage, and lymph node metastasis ( p = 0.000, p = 0.016, and p = 0.001, respectively). Conversely, lost HLA-I expression did not have any associations with clinicopathological data ( p > 0.05). Survivin-negative patients had a higher tumor-free survival rate than patients with survivin expression ( p = 0.037). Patients with normal HLA-I levels had a higher tumor-free survival rate than those with reduced HLA-I levels ( p = 0.02). The uni- and multivariate analyses indicated that expression of survivin and HLA-I, individually and in combination, was an independent predictor for survival of ccRCC patients. Overexpression of survivin but reduced HLA-I expression is useful in the prediction of tumor-free survival of ccRCC patients.